Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women

María Rebeca Massai, Soledad Díaz, Eliana Quinteros, María Verónica Reyes, Carmen Herreros, Ana Zepeda, Horacio B. Croxatto, Alfred J. Moo-Young

Resultado de la investigación: Article

38 Citas (Scopus)

Resumen

The objective of this study was to evaluate the contraceptive efficacy and clinical performance of a Nestorone subdermal implant (NES) in the postpartum period. NES (n = 100) and Copper T intrauterine device (T-Cu; n = 100) acceptors initiated contraception at 8 weeks postpartum and were followed at monthly intervals during the first year and at 3-month intervals thereafter. Pregnancy rates, breastfeeding performance, infant growth, bleeding pattern, and side effects were assessed. Blood and milk NES concentration were measured. No pregnancy occurred in 2195 and 2145 woman-months of NES implant and T-Cu use, respectively. No effect of NES on lactation and infant growth and no serious adverse events were observed. Lactational amenorrhea was significantly longer in NES users (353 ± 20 days) than in T-Cu users (201 ± 11 days). More NES users (55.8%) experienced prolonged bleedings than did T-Cu users (36.2%). Concentrations of NES in breast milk ranged between 54-135 pmol/liter. The Nestorone implant is a highly effective contraceptive, safe for breastfed infants because the steroid is inactive by the oral route.

Idioma originalEnglish
Páginas (desde-hasta)369-376
Número de páginas8
PublicaciónContraception
Volumen64
N.º6
DOI
EstadoPublished - 1 dic 2001

Huella dactilar

Contraceptive Agents
Postpartum Period
Copper Intrauterine Devices
Hemorrhage
ST 1435
Amenorrhea
Human Milk
Pregnancy Rate
Growth
Breast Feeding
Contraception
Lactation
Milk
Steroids
Pregnancy

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Citar esto

Massai, M. R., Díaz, S., Quinteros, E., Reyes, M. V., Herreros, C., Zepeda, A., ... Moo-Young, A. J. (2001). Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception, 64(6), 369-376. https://doi.org/10.1016/S0010-7824(01)00259-1
Massai, María Rebeca ; Díaz, Soledad ; Quinteros, Eliana ; Reyes, María Verónica ; Herreros, Carmen ; Zepeda, Ana ; Croxatto, Horacio B. ; Moo-Young, Alfred J. / Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. En: Contraception. 2001 ; Vol. 64, N.º 6. pp. 369-376.
@article{5ce40ccc63194c1f8562788636861aca,
title = "Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women",
abstract = "The objective of this study was to evaluate the contraceptive efficacy and clinical performance of a Nestorone subdermal implant (NES) in the postpartum period. NES (n = 100) and Copper T intrauterine device (T-Cu; n = 100) acceptors initiated contraception at 8 weeks postpartum and were followed at monthly intervals during the first year and at 3-month intervals thereafter. Pregnancy rates, breastfeeding performance, infant growth, bleeding pattern, and side effects were assessed. Blood and milk NES concentration were measured. No pregnancy occurred in 2195 and 2145 woman-months of NES implant and T-Cu use, respectively. No effect of NES on lactation and infant growth and no serious adverse events were observed. Lactational amenorrhea was significantly longer in NES users (353 ± 20 days) than in T-Cu users (201 ± 11 days). More NES users (55.8{\%}) experienced prolonged bleedings than did T-Cu users (36.2{\%}). Concentrations of NES in breast milk ranged between 54-135 pmol/liter. The Nestorone implant is a highly effective contraceptive, safe for breastfed infants because the steroid is inactive by the oral route.",
keywords = "Amenorrhea, Breastfeeding, Contraception, Copper T-IUD, Nestorone implant, Nursing women",
author = "Massai, {Mar{\'i}a Rebeca} and Soledad D{\'i}az and Eliana Quinteros and Reyes, {Mar{\'i}a Ver{\'o}nica} and Carmen Herreros and Ana Zepeda and Croxatto, {Horacio B.} and Moo-Young, {Alfred J.}",
year = "2001",
month = "12",
day = "1",
doi = "10.1016/S0010-7824(01)00259-1",
language = "English",
volume = "64",
pages = "369--376",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "6",

}

Massai, MR, Díaz, S, Quinteros, E, Reyes, MV, Herreros, C, Zepeda, A, Croxatto, HB & Moo-Young, AJ 2001, 'Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women', Contraception, vol. 64, n.º 6, pp. 369-376. https://doi.org/10.1016/S0010-7824(01)00259-1

Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. / Massai, María Rebeca; Díaz, Soledad; Quinteros, Eliana; Reyes, María Verónica; Herreros, Carmen; Zepeda, Ana; Croxatto, Horacio B.; Moo-Young, Alfred J.

En: Contraception, Vol. 64, N.º 6, 01.12.2001, p. 369-376.

Resultado de la investigación: Article

TY - JOUR

T1 - Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women

AU - Massai, María Rebeca

AU - Díaz, Soledad

AU - Quinteros, Eliana

AU - Reyes, María Verónica

AU - Herreros, Carmen

AU - Zepeda, Ana

AU - Croxatto, Horacio B.

AU - Moo-Young, Alfred J.

PY - 2001/12/1

Y1 - 2001/12/1

N2 - The objective of this study was to evaluate the contraceptive efficacy and clinical performance of a Nestorone subdermal implant (NES) in the postpartum period. NES (n = 100) and Copper T intrauterine device (T-Cu; n = 100) acceptors initiated contraception at 8 weeks postpartum and were followed at monthly intervals during the first year and at 3-month intervals thereafter. Pregnancy rates, breastfeeding performance, infant growth, bleeding pattern, and side effects were assessed. Blood and milk NES concentration were measured. No pregnancy occurred in 2195 and 2145 woman-months of NES implant and T-Cu use, respectively. No effect of NES on lactation and infant growth and no serious adverse events were observed. Lactational amenorrhea was significantly longer in NES users (353 ± 20 days) than in T-Cu users (201 ± 11 days). More NES users (55.8%) experienced prolonged bleedings than did T-Cu users (36.2%). Concentrations of NES in breast milk ranged between 54-135 pmol/liter. The Nestorone implant is a highly effective contraceptive, safe for breastfed infants because the steroid is inactive by the oral route.

AB - The objective of this study was to evaluate the contraceptive efficacy and clinical performance of a Nestorone subdermal implant (NES) in the postpartum period. NES (n = 100) and Copper T intrauterine device (T-Cu; n = 100) acceptors initiated contraception at 8 weeks postpartum and were followed at monthly intervals during the first year and at 3-month intervals thereafter. Pregnancy rates, breastfeeding performance, infant growth, bleeding pattern, and side effects were assessed. Blood and milk NES concentration were measured. No pregnancy occurred in 2195 and 2145 woman-months of NES implant and T-Cu use, respectively. No effect of NES on lactation and infant growth and no serious adverse events were observed. Lactational amenorrhea was significantly longer in NES users (353 ± 20 days) than in T-Cu users (201 ± 11 days). More NES users (55.8%) experienced prolonged bleedings than did T-Cu users (36.2%). Concentrations of NES in breast milk ranged between 54-135 pmol/liter. The Nestorone implant is a highly effective contraceptive, safe for breastfed infants because the steroid is inactive by the oral route.

KW - Amenorrhea

KW - Breastfeeding

KW - Contraception

KW - Copper T-IUD

KW - Nestorone implant

KW - Nursing women

UR - http://www.scopus.com/inward/record.url?scp=0035709168&partnerID=8YFLogxK

U2 - 10.1016/S0010-7824(01)00259-1

DO - 10.1016/S0010-7824(01)00259-1

M3 - Article

C2 - 11834236

AN - SCOPUS:0035709168

VL - 64

SP - 369

EP - 376

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 6

ER -

Massai MR, Díaz S, Quinteros E, Reyes MV, Herreros C, Zepeda A y otros. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception. 2001 dic 1;64(6):369-376. https://doi.org/10.1016/S0010-7824(01)00259-1